Morning Overview on MSN

Seven years on, most lung cancer patients on one drug had no progression

More than half of patients with advanced ALK-positive lung cancer who started on lorlatinib seven years ago still have not ...
The University of Alabama at Birmingham

UAB trial shows first-in-human immunotherapy that more than doubles progression-free survival in glioblastoma patients

UAB researchers report Phase 1 trial results showing a novel immunotherapy safely doubled the time glioblastoma patients ...
CNN

How well a cancer treatment works may depend on the time of day you get it

EDITOR’S NOTE: The Nature Medicine study on timing of immunotherapy and survival of cancer patients was retracted by the journal on June 24, 2026. After an investigation into discrepancies identified ...
ascopubs.org

Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial

Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer Patients age 20 years and ...
Cure Today

No Man’s Land: When Metastatic Breast Cancer Responds Long-Term

Multidisciplinary tumor board endorsement enabled locoregional surgery and radiation in de novo metastatic disease, reflecting selective use of curative-intent paradigms in exceptional responders.

First-in-human immunotherapy more than doubles progression-free survival in glioblastoma patients

Glioblastoma, the most aggressive malignant brain tumor in adults, remains one of the most challenging cancers to treat ...